Mayne Pharma Group Ltd. · ASX:MYX
Mayne Pharma — Shareholder Meeting (November 2017)
12 slides from Mayne Pharma's shareholder meeting presentation, Nov 28, 2017
Slide 1: Mayne Pharma Group Limited Annual General Meeting
For personal use only Mayne Pharma Group Limited Annual General Meeting 28 November 2017 1
Slide 2: US generic industry dynamics
US generic industry dynamics For personal use only ● Consolidation of customers and payers Share Price Performance (% change) ● Acceleration of generic approvals by FDA Company 1-Year 2-Year 3-Year 5-Year ● Aggressive competition and pricing activities impacting the generic (60%) (45%) (9%) +150% ma
Slide 3: FY17 key financial metrics
FY17 key financial metrics1 For personal use only Reported basis Reported basis EBITDA NPAT Reported basis A$204.0m, +165% A$88.6m, +137% Revenue A$572.6m, +114% Underlying basis Reported basis EBITDA2 EPS A$206.5m, +133% 6.2 cents, +30% • (1) EBITDA and NPAT is profit attributable to member
Slide 4: Generic Products Division (GPD)
Generic Products Division (GPD) For personal use only ● FY17 revenue increased by 292% to A$419m ● FY17 gross profit increased by 259% to A$218m ● Dofetilide became largest selling generic product ● Teva acquired products delivered revenue of US$180m and EBITDA of US$90m ● Accelerated price deflatio
Slide 5: Specialty Brands Division (SBD)
Specialty Brands Division (SBD) For personal use only ● FY17 revenue down 20% to A$62m ● FY17 gross profit down 20% to A$59m ● Impacted by loss of exclusivity on Doryx® 50mg and 200mg tablets in May 2016 ● Stronger performance in 2H17 driven by launch of Fabior® and Sorilux® in January 2017 ● Both F
Slide 6: Metrics Contract Services (MCS)
Metrics Contract Services (MCS) For personal use only ● FY17 revenue up 18% to A$58m New fluid bed spray coater and stability centre ● FY17 gross profit up 22% to A$32m ● Growing customer demand for end to end solutions ● Greenville facility expansions and investment in new technical equipment attra
Slide 7: Mayne Pharma International (MPI)
Mayne Pharma International (MPI) For personal use only ● FY17 revenue up 2% to A$34m ● FY17 gross profit down 13% to A$7m ● Australian sales benefited from sales growth in Lozanoc® and oxycodone; offset by softer Kapanol® and injectable sales ● Gross profit decline reflects reduced one-off licensing
Slide 8: Greenville campus – nearing completion
Greenville campus – nearing completion For personal use only 8
Slide 9: Year to date October trading
Year to date October trading For personal use only ● Revenue down 12% to A$151m impacted by generic competitive pricing pressures, abnormal Doryx® returns and lower SBD trade volumes ● Gross profit impacted by abnormal Doryx® returns and also one-off extraordinary stock obsolescence in GPD ─ Gross p
Slide 10: SUBA-Itraconazole franchise has multiple opportunities for growth
SUBA-Itraconazole franchise has multiple opportunities for growth For personal use only Anti-fungal Oncology ● Approved in Australia, Spain, Germany, UK, Italy, ● Partnered with the US listed HedgePath Portugal, Belgium and Austria Pharmaceuticals Inc. (OTCQX: HPPI) to pursue the clinical developmen
Slide 11: Phase IIb study in BCCNS patients
Phase IIb study in BCCNS patients For personal use only ● 38 patients treated to date 100% ─ 10 patients in active treatment ─ 10 patients in follow up 75% ─ 18 patients off study 50% ● 195 BCC excisions per patient % change from BL 25% prior to the study 0% ● Only one surgery for a BCC target -25%
Slide 12: Phase IIb study in BCCNS patients (cont.)
Phase IIb study in BCCNS patients (cont.) For personal use only ● Median time on study 38 weeks ● Up to 90 weeks on study for some patients ● Very good safety profile with only 11% of patients discontinued due to adverse events ● No hair loss ● No loss of taste ● No severe muscle spasms Durable resp
Mayne Pharma Group — Shareholder Meeting (November 2017) on 6ix